HCEG Healthcare Ent.

RNS Number:1800B
Healthcare Enterprise Group PLC
26 July 2004


Healthcare Enterprise Group plc

Ebiox surface cleaning product passes tests required for US Environment
Protection Agency approval

Healthcare Enterprise Group PLC ("HCEG"), the healthcare products and services
company, announces that its Trionic Plus product from the Ebiox family of
products has passed tests required for US Environment Protection Agency (EPA).
EPA approval will allow the product to be offered to US hospitals and related
facilities and for industrial antimicrobial and other cleaning uses in the US.

Trionic Plus is a high power "terminal" disinfectant proven to be effective at
combating MRSA and other pathogens.  HCEG believes that the product offers
significant safety advantages over all other commonly used disinfectants and
does not contain alcohol, chlorine or other irritating vapours.

Trionic Plus contains soil lifting agents and biocides, which allow removal of
soils and microbes down to the molecular level.  It removes the invisible
surface biofilms, which are believed to provide a rich breeding ground for the
development of resistant bacteria.

For high-risk contaminated areas Trionic Plus provides a fast-kill solution for
bacteria on hygienic surfaces such as floors, walls, tables, beds and public
access areas.  Unlike other commonly used surface cleaners, Trionic Plus works
by oxidation rather than toxification.  This means that there is no need to
rotate disinfectants because there is no chance of bacterial resistance
developing.

HCEG is considering a range of US marketing and distribution options for Trionic
Plus, together with similar strategies for its surgical instrument cleaner
range, which received EPA approval in March.

Stuart Bruck, Chairman, Healthcare Enterprise Group PLC, commented:

"The US represents over half of the world's healthcare economy, with an annual
expenditure in excess of US$1.7 trillion and is a market with which we are
familiar.  The sheer size of the market means entry into the US represents an
exciting opportunity for the Ebiox product range.

Since the US tends to lead in the adoption of new healthcare technologies, we
are confident that the obvious benefits these products have over existing
alcohol or bleach disinfectants will result in active product investigation and
assessment by US hospitals and other healthcare facilities."

26 July 2004

Enquiries:

Healthcare Enterprise Group                                        020 7351 7500
   Stuart Bruck                    Executive Chairman
   Gordon Wood                     Group Chief Operating Officer

College Hill                                                       020 7457 2020
   Nicholas Nelson
   Corinna Dorward

Note to editors

Ebiox

Ebiox produces a range of patented cleansing, decontamination and disinfectant
products.  The range includes hand hygiene products, hard surface cleaners,
disinfectants and products to clean and decontaminate surgical instruments.

Ebiox antibacterial handwash and handrub are proven effective against MRSA,
E-coli and other important pathogens and are fully compliant with EU standards.
Uniquely, the products do not use alcohol, which has a drying effect and can be
a skin irritant.

The hard surface cleaners, particularly the Trionic Plus trigger spray and
Azowipe Active wipes are based on a lifting and removing concept, completely
removing biofilms and cleaning to molecular level.  The product continues to be
active after use and cleans through oxidation action, not toxification which
means that there is no need to rotate disinfectants because there is no chance
of resistance developing (cf GMP guidelines).

Ebiox also offers a range of products for the effective cleaning of re-usable
instruments.  Critically, these products remove all debris prior to the
sterilisation process thereby ensuring complete decontamination.  They have
proven to be more effective than natural detergents and enzymatic detergents
currently available.

As well as the current range of products, Ebiox also has products for the
decontamination of dental aspiration lines and a veterinary product range,
EbioxVET.

Healthcare Enterprise Group PLC

HCEG is quoted on the UK AIM stock market with its head office in London and
subsidiary offices in Manchester, Liverpool, Cheshire, Germany and the USA.
HCEG is a business engaged in medical product distribution, occupational health,
first aid and medical consultancy markets.  These businesses underpin a range of
innovative medical devices, which will be introduced to the market via HCEG's
own distribution network on an international  basis.

HCEG owns 51% of the shares in Ebiox Ltd, a management contract for the business
and options to acquire up to 100% of Ebiox Ltd.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END

MSCQKNKQPBKDQOB

Healthcare Enterprise (LSE:HCEG)
Historical Stock Chart
From Jun 2024 to Jul 2024

Healthcare Enterprise (LSE:HCEG)
Historical Stock Chart
From Jul 2023 to Jul 2024